Hyperphosphatemia Drugs Market

Hyperphosphatemia Drugs Market Size:

The global hyperphosphatemia drugs market size reached USD 4.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 7.07% during 2024-2032. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:

Increasing Incidents of Chronic Kidney Disease (CKD)

The global escalation in prevalence of chronic kidney disease (CKD) is a major trend contributing to the expansion of the hyperphosphatemia drugs market size. With the progression of CKD, patients generally suffer from hyperphosphatemia due to defective phosphate excretion. Consequently, this condition results in an elevated requirement for phosphate-binding medicines to balance the phosphate levels. Furthermore, the magnification of aging population and growing cases of hypertension and diabetes worldwide, which are major causes of CKD, are supporting the expanding market for hyperphosphatemia treatments. In addition, as the CKD patient population grows significantly, so does the demand for efficient management of hyperphosphatemia, thereby propelling market growth. According to a research article published in the journal Nature Reviews Nephrology in April 2024, around 850 million individuals globally are living with kidney disease. Additionally, CKD is anticipated to become the 5th leading cause of years of life lost (YLL) by the year 2040.

Innovations in Phosphate Binder Medications

The formulation of more efficient and newer phosphate binders is another key trend significantly impacting the expansion of global hyperphosphatemia drugs market size. Advancements in drug development, like non-calcium-based phosphate binders, have notably enhanced the treatment efficacy of hyperphosphatemia, especially in minimizing the risks of hypercalcemia. For instance, a study published in the Journal of Clinical Medicine in December 2023 revealed that sevelamer, most used non-calcium-based phosphate binder, has significant benefits for patients suffering with stage 4 or 5 CKD. This drug is associated with a 63% reduction in cardiovascular mortality and 56% reduction in all-cause mortality, highlighting its exceptional efficacy in enhancing patient outcomes. Moreover, such innovation acknowledges major concerns associated to conventional phosphate binders, providing improved adherence and patient outcomes. In addition, the production of more effective drugs with minimal side effects is appealing several healthcare professionals, resulting in an elevated rate of adoption, and substantially contributing to the market expansion in emerging as well as developed regions.

Rising Awareness and Diagnosis of Hyperphosphatemia

Growing awareness of hyperphosphatemia and its complications, particularly among healthcare providers treating CKD patients, is significantly contributing to market growth. Early diagnosis and improved screening of hyperphosphatemia are chiefly propelling the demand for phosphate-lowering therapies. Moreover, educational programs by healthcare organizations, coupled with more strategic approaches to tackle CKD-related conditions, are facilitating the early treatment of hyperphosphatemia. Furthermore, the rising case of hyperphosphatemia is spurring the demand for diagnosis options. According to a research article published in the journal Medicina in May 2023, hyperphosphatemia is the most prevailing CKD-associated disorder, impacting around 50%-70% of renal disorders patients. This trend, combined with advanced healthcare infrastructure in emerging regions, is further extending access to hyperphosphatemia treatment and fueling the overall growth of the global market. According to industry reports, China, a major emerging economy with robust healthcare infrastructure, witnessed significant expansion in healthcare expenditure, with public funding rising to around $307.9 billion in 2023.

Hyperphosphatemia drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, dosage form, and distribution channel.

Product Insights:

• Sevelamer
• Calcium Based Phosphate Binders
• Iron Based Phosphate Binders
• Lanthanum Carbonate
• Others
   

The report has provided a detailed breakup and analysis of the market based on the product. This includes sevelamer, calcium based phosphate binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.

Dosage Form Insights:

• Tablets
• Syrups
• Capsules
   

A detailed breakup and analysis of the market based on the dosage form have also been provided in the report. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
   

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hyperphosphatemia drugs. Some of the factors driving the hyperphosphatemia drugs market share in North America includes the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Ardelyx Inc.
• Fresenius Medical Care AG & Co. KGaA
• Lupin Pharmaceuticals Inc (Lupin Limited)
• Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
• Vifor Pharma Management Ltd. (CSL Limited)
   

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Hyperphosphatemia drugs Market News:

• In September 2024, Unicycive Therapeutics, Inc., a major biotechnology company for renal drugs, announced the submission of its newly developed Oxylanthanum Carbonate (OLC) drug to FDA. This drug is next-gen lanthanum-based phosphate binder that leverages nanoparticles technology and is particularly formulated for hyperphosphatemia treatment in CKD patients.
• In January 2024, LG Chem announced strategic cooperation with Kyowa Kirin, a Japan-based biotechnology and pharmaceutical company, to co-market Nephoxil, Kyowa's hyperphosphatemia drug, expanding its brand value.
• In October 2023, Ardelyx, Inc., a prominent biopharmaceutical company, announced the receival of FDA approval for XPHOZAH (tenapanor), its newly developed hyperphosphatemia drug that can effectively block phosphate absorption.

Hyperphosphatemia drugs Market Report Scope:

Key Questions Answered in This Report:

• How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
• What are the key regional markets?
• Which countries represent the most attractive hyperphosphatemia drugs markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the dosage form?
• What is the breakup of the market based on the distribution channel?
• What is the competitive structure of the global hyperphosphatemia drugs market?
• Who are the key players/companies in the global hyperphosphatemia drugs market?
   

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the hyperphosphatemia drugs market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global hyperphosphatemia drugs market.
• The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the hyperphosphatemia drugs industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.